The treatment with CF-EO inhibits melanogenesis by inhibiting tyrosinase activity and by reducing TRP-1 and TRP-2, co-stimulated with α-MSH and forskolin (FSK), in B16F10 melanoma [172]. This evidence concerns the gene STAMBP and melanoma.